Literature DB >> 29521120

Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis.

Anthony L Byrne1,2,3, Greg J Fox4, Ben J Marais5.   

Abstract

Diagnostic and treatment delays contribute to increased death and disability among the 490,000 adults and children who develop multidrug-resistant (MDR) tuberculosis every year. Since the treatment of MDR tuberculosis is complex, costly and often toxic, tuberculosis control programs should prioritize strategies to prevent drug-resistant tuberculosis. Opportunities to limit transmission and prevent disease progression in close contacts of MDR tuberculosis cases are often neglected. Effective MDR tuberculosis preventive strategies could minimize the costs for patients and healthcare systems. This review characterizes the biological basis for the development of MDR tuberculosis, outlines the evidence for strategies to reduce transmission and highlights programmatic approaches to the management of patients infected with drug-resistant strains of Mycobacterium tuberculosis.

Entities:  

Keywords:  multidrug resistant; prevention; tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 29521120     DOI: 10.2217/fmb-2017-0236

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  2 in total

1.  Detailed characterisation of the tuberculosis epidemic in Western Sydney: a descriptive epidemiological study.

Authors:  Sophie Norton; Shopna K Bag; Jin-Gun Cho; Neil Heron; Hassan Assareh; Laila Pavaresh; Stephen Corbett; Ben J Marais
Journal:  ERJ Open Res       Date:  2019-09-10

2.  Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.

Authors:  Greg J Fox; Cam Binh Nguyen; Thu Anh Nguyen; Phuong Thuy Tran; Ben J Marais; Steve M Graham; Binh Hoa Nguyen; Kavi Velen; David W Dowdy; Paul Mason; Warwick J Britton; Marcel A Behr; Andrea Benedetti; Dick Menzies; Viet Nhung Nguyen; Guy B Marks
Journal:  BMJ Open       Date:  2020-01-02       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.